European Union Leadership Critical for Affordable & Responsible Antibiotic R&D

Policy Report | 23 May, 2017 | Download PDF

Antimicrobial resistance (AMR) is a global threat, which refers to microbes becoming resistant to antimicrobial medicines developed to treat them. Every time an antibiotic medicine is used, it increases the possibility of the microbe becoming resistant. Currently, AMR causes an estimated 25,000 deaths per year in the European Union (EU) and 700,000 worldwide.

Proposed Changes to EMA’s Access to Documents Policy Fall Short on Proactive Disclosure

Press Release | 18 May, 2017 | Download PDF

BRUSSELS—The European Medicines Agency’s (EMA) proposed amendments to its access to documents policy do not sufficiently ensure comprehensive access to documents, say medicines policy watchdog organisations, Health Action International, the International Society of Drug Bulletins, NoGracias, the Nordic Cochrane Centre and Prescrire.

Joint Letter to World Health Assembly Delegates | We must delink research and development costs from cancer medicine prices

Joint Letter | 5 May 2017 | Download

Health Action International have added our name to a letter to all delegates to the World Health Assembly (WHA). The letter – supported by NGOs, economists, legal advisors and individual experts – calls on all delegates to support a draft resolution that would establish a feasibility study to be conducted on the delinkage of research and development costs from cancer medicine prices.

Response to OECD Online Consultation ‘Sustainable access to innovative therapies’

OECD Consultation Response | 28 April 2017 | Click here to download

Health Action International has submitted a response to an online consultation by the Organisation for Economic Co-operation and Development (OECD) on the ways to improve the sustainability of access to innovative therapies. In the consultation response, we identify major issues that need to be addressed to improve access to medicines and make a series of recommendations on how the OECD can address them.

ACCISS Study Report | Biosimilar Insulin Regulatory Profile

ACCISS Study Report | 6 April 2017 –  Report | Fact Sheet

The Biosimilar Insulin Regulatory Profile discusses the regulatory pathways and challenges faced by companies seeking marketing authorisation for insulin biosimilars, particularly in highly-regulated markets such as the European Union (EU) and the United States (US).  It also includes a case study of two manufacturers who sought marketing authorisation from the European Medicines Agency (EMA) for insulin products.

2016 Annual Report & Financial Statements

2016 Annual Report & Financial Statements | 5 April, 2017 | Download PDF

About Health Action International
Health Action International (HAI) is the only independent, non-profit, civil society organisation entirely dedicated to improving access to medicines and the rational use of medicines. As a
Dutch-registered ‘stichting’ (foundation) established in 1981,

Report | The Sun Shines on Europe: transparency of financial relationships in the healthcare sector

Report | 29 March 2017 | Download PDF

Pharmaceutical companies employ a wide range of promotional activities to increase medicines prescription rates and maximise their profit. Some of the strategies companies use to influence healthcare professionals include the provision of hospitality to attend events, free meals and gift-giving. At the same time,

ACCISS Study Report | Access to Insulin: Current Challenges and Constraints

ACCISS Study Report | 23 March 2017 | Download PDF

Executive Summary

The Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS) Study has completed its first phase of work, which aimed to gain an overall understanding of the insulin market through different profiles. These included profiles on the insulin market,